VIVS

$0.00

(

0.00%

)
Quote details

stock

VivoSim Labs, Inc.

NASDAQ | VIVS

2.96

USD

$0.00

(

0.00%

)

At Close (As of Oct 13, 2025)

$5.15M

Market Cap

-

P/E Ratio

-1.7

EPS

$21.96

52 Week High

$1.41

52 Week Low

HEALTHCARE

Sector

VIVS Chart

Recent Chart
Price Action

VIVS Technicals

Tags:

VIVS Earnings

Yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit $139K
Total Revenue $144K
Cost Of Revenue $5K
Costof Goods And Services Sold $5K
Operating Income -$13M
Selling General And Administrative $7.7M
Research And Development $5M
Operating Expenses $13M
Investment Income Net -
Net Interest Income $130K
Interest Income $140K
Interest Expense $10K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $266K
Income Before Tax -$2.5M
Income Tax Expense $2K
Interest And Debt Expense -
Net Income From Continuing Operations -$2.5M
Comprehensive Income Net Of Tax -
Ebit -$2.5M
Ebitda -$2.2M
Net Income -$2.5M

Revenue & Profitability

Earnings Performance

VIVS Financials

yearly Balance Sheet (As of Mar 31, 2025)

Field Value (USD)
Total Assets $15M
Total Current Assets $12M
Cash And Cash Equivalents At Carrying Value $11M
Cash And Short Term Investments $11M
Inventory $0
Current Net Receivables $30K
Total Non Current Assets $2.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $789K
Other Non Current Assets -
Total Liabilities $4.2M
Total Current Liabilities $3.7M
Current Accounts Payable $1.6M
Deferred Revenue -
Current Debt -
Short Term Debt $521K
Total Non Current Liabilities $421K
Capital Lease Obligations $942K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $942K
Other Current Liabilities $1.6M
Other Non Current Liabilities -
Total Shareholder Equity $10M
Treasury Stock -
Retained Earnings -$342M
Common Stock $2K
Common Stock Shares Outstanding $1.5M

yearly Cash Flow (As of Mar 31, 2025)

Field Value (USD)
Operating Cashflow -$9.5M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $266K
Capital Expenditures $13K
Change In Receivables -
Change In Inventory -$501K
Profit Loss -
Cashflow From Investment $9M
Cashflow From Financing $8.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$2.5M

yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit $139K
Total Revenue $144K
Cost Of Revenue $5K
Costof Goods And Services Sold $5K
Operating Income -$13M
Selling General And Administrative $7.7M
Research And Development $5M
Operating Expenses $13M
Investment Income Net -
Net Interest Income $130K
Interest Income $140K
Interest Expense $10K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $266K
Income Before Tax -$2.5M
Income Tax Expense $2K
Interest And Debt Expense -
Net Income From Continuing Operations -$2.5M
Comprehensive Income Net Of Tax -
Ebit -$2.5M
Ebitda -$2.2M
Net Income -$2.5M

VIVS News

VIVS Profile

VivoSim Labs, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

VivoSim Labs, Inc. is a pioneering biotechnology firm based in San Diego, California, dedicated to revolutionizing disease modeling through the development of advanced 3D tissue technologies. By creating biomimetic tissues that accurately reflect the complexities of human diseases, the company aims to enhance drug discovery, disease understanding, and therapeutic approaches. With a commitment to innovation, VivoSim is positioned to play a critical role in the future of personalized medicine and regenerative therapies, addressing unmet medical needs and driving advancements in the biopharmaceutical industry.

VHAI
+66.66%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
NVTS
+21.14%
$9.97
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
AMD
+0.70%
$216.42
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
APLD
+0.73%
$34.24
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
LAES
+13.30%
$6.13
DVLT
-10.52%
$1.70
ONDS
+17.24%
$10.81
RR
+8.95%
$6.45
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
IONQ
+16.19%
$82.09
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
NOK
-1.31%
$5.25
MARA
+8.52%
$20.23
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
VHAI
+66.66%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
NVTS
+21.14%
$9.97
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
AMD
+0.70%
$216.42
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
APLD
+0.73%
$34.24
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
LAES
+13.30%
$6.13
DVLT
-10.52%
$1.70
ONDS
+17.24%
$10.81
RR
+8.95%
$6.45
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
IONQ
+16.19%
$82.09
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
NOK
-1.31%
$5.25
MARA
+8.52%
$20.23
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.